PMEF
ANIP icon

Point72 Middle East FZE’s ANI Pharmaceuticals ANIP Stock Holding History

Point72 Middle East FZE’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-901
Closed -$52.3K – 1482
2023
Q3 		$52.3K Buy
901
+795
+750% +$45.9K ﹤0.01% 1237
2023
Q2 		$5.71K Sell
106
-520
-83% -$23.1K ﹤0.01% 1441
2023
Q1 		$24.9K Buy
+626
New +$26.4K ﹤0.01% 1387

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Point72 Middle East FZE's ANIP Position: Q4 2023 in Review

Point72 Middle East FZE sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 901 shares — an estimated $52.3K sold.

Point72 Middle East FZE first reported a position in ANIP in Q1 2023 and held it in 3 quarters. The position peaked at $52.3K in Q3 2023. 182 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

  • Point72 Middle East FZE reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 901 ANI Pharmaceuticals shares in Q4 2023, an estimated $52.3K.
  • Point72 Middle East FZE first reported a position in ANI Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's ANI Pharmaceuticals position peaked at $52.3K in Q3 2023.
  • 182 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.